GGrantIndex
← Leaderboards

Daniel Alan Heller

Sloan-Kettering Inst Can Research

$9,871,986
Attributed
$12,007,735
Total exposure
7
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.7M · FY201225
$5M$3.8M$2.5M$1.3M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$12,007,735 · 7

By mechanism

R01$8,953,391 · 4
DP2$2,743,500 · 1
R43$305,844 · 1
R13$5,000 · 1

Top collaborators

Most similar at Sloan-Kettering Inst Can Research

Same institution · by research overlap

Others in their field

Top investigators on “Pharmaceutical Preparations

Research focus

Pharmaceutical PreparationsTechnologyDrug Delivery SystemsNanoparticleToxic EffectBiodistributionDrug KineticsMeasurementTargeted TreatmentEndotheliumTherapeutic IndexResearch PersonnelMediatingGenomicsExhibitsCancer CellTumor TissueNovel Therapeutic InterventionNeoplasm MetastasisNeoplastic CellEndothelial CellsNovel StrategiesDrug TargetingAffinity

Grant awards (19)

Nanosensor Array Platform to Capture Whole Disease Fingerprints$643,764
R01 · FY2025 · EB · contact PI
2025 Cancer Nanotechnology Gordon Research Conference and Gordon Research Seminar$5,000
R13 · FY2025 · CA · contact PI
Nanosensor Array Platform to Capture Whole Disease Fingerprints$640,165
R01 · FY2024 · EB · contact PI
Tumor-Selective Delivery Approaches for Medulloblastoma$577,523
R01 · FY2024 · NS · contact PI
Nanosensor Array Platform to Capture Whole Disease Fingerprints$696,587
R01 · FY2023 · EB · contact PI
Tumor-Selective Delivery Approaches for Medulloblastoma$603,031
R01 · FY2023 · NS · contact PI
P-selectin-Mediated Targeting of PI3K Nanomedicines to the Tumor Microenvironment$626,484
R01 · FY2022 · CA · contact PI
Tumor-Selective Delivery Approaches for Medulloblastoma$608,977
R01 · FY2022 · NS · contact PI
P-selectin-Mediated Targeting of PI3K Nanomedicines to the Tumor Microenvironment$639,270
R01 · FY2021 · CA · contact PI
Tumor-Selective Delivery Approaches for Medulloblastoma$615,717
R01 · FY2021 · NS · contact PI
Efficacy and pharmacokinetic assessment of renal-targeted therapy in a pig model of cisplatin induced acute kidney injury.$305,844
R43 · FY2021 · DK
Tumor-Selective Delivery Approaches for Medulloblastoma$662,109
R01 · FY2020 · NS · contact PI
P-selectin-Mediated Targeting of PI3K Nanomedicines to the Tumor Microenvironment$639,270
R01 · FY2020 · CA · contact PI
Renal tubule-specific nanotherapeutics for acute kidney injury$269,400
R01 · FY2020 · DK · contact PI
P-selectin-Mediated Targeting of PI3K Nanomedicines to the Tumor Microenvironment$592,815
R01 · FY2019 · CA · contact PI
Renal tubule-specific nanotherapeutics for acute kidney injury$269,400
R01 · FY2019 · DK · contact PI
P-selectin-Mediated Targeting of PI3K Nanomedicines to the Tumor Microenvironment$611,329
R01 · FY2018 · CA · contact PI
Renal tubule-specific nanotherapeutics for acute kidney injury$257,550
R01 · FY2018 · DK · contact PI
Transient Metabolite Detection for Single-Cell Metabolomics and Diagnostics$2,743,500
DP2 · FY2012 · HD · contact PI